ITGA3 and pancreatic neoplasm: PACA-AU, PAAD-US-TCGA, GSE79688, GSE62452, GSE57495, and GSE17891 datasets revealed that low expression of ITGα3 significantly improved median survival (MS) compared with a high expression of ITGα3 in patients with pancreatic cancer (Fig. 4A–F).